Christina H. Yeon, M.D.

  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
  • Medical Oncologist/Hematologist

Christina H. Yeon, M.D.

Clinical Specialties
  • Medical Oncology
  • Hematology
Areas of Expertise
  • Breast Cancer
Research Focus
  • Breast Cancer

Voted on multiple occasions by her peers as one of Pasadena Magazine’s “Best Physicians of the San Gabriel Valley,” Christina Haeyoung Yeon, M.D., has practiced oncology and hematology in Pasadena, California, since 2004. She has extensive experience in the diagnosis and treatment of all adult malignancies as well as benign/malignant hematologic disorders with a special interest in breast oncology.

Dr. Yeon is board certified in medical oncology and hematology. She completed all of her higher education at University of California, Los Angeles (UCLA), including a bachelor’s degree in biochemistry, medical doctorate, internal medicine residency and combined medical oncology/hematology fellowship.

Dr. Yeon is intimately involved in clinical research efforts conducted at our community practice sites. She has been a key member of City of Hope’s South Pasadena team since joining the practice in 2011.

  • 2011 – present, Physician in Hematology/Oncology and Physician Lead, City of Hope, South Pasadena, CA
  • 2004 - 2011, Physician, Wilshire Oncology Medical Group Inc., Pasadena, CA

Locations

South Pasadena

209 Fair Oaks Ave., South Pasadena, CA, 91030

Get Directions

Phone :  877-998-7546

Degrees

  • 1998, UCLA, CA, awarded M.D.
  • 1994, UCLA, CA, Bachelor of Science, biochemistry, Summa Cum Laude

Fellowship

  • 2001 -2004, Fellow, Hematology/Oncology, UCLA (University of California, Los Angeles), CA

Residency

  • 1999 -2001, Resident, Internal Medicine, UCLA, CA

Internship

  • 1998 -1999, Intern, Internal Medicine, UCLA, CA
  • California State Medical License - Active
  • 2005, American Board of Internal Medicine - Subspecialty of Hematology
  • 2004, American Board of Internal Medicine - Subspecialty of Medical Oncology
  • 2001, American Board of Internal Medicine
G Upadhyaya, CA Presant, L Bosserman, A Estrella, A Greenburg, A Der, C Yeon, M Vakil, R Horns and B Ebrahimi. Wilshire Oncology Medical Group, La Verne, California. "Internet (Int) oncology (Onc) information (Inf) services: access and usage by oncology patients (pt) in 2006: the project for internet patient education (PIPE) program. Submitted, Amer Soc Clin Oncol, 2007.
 
C.A. Presant, L. Bosserman, C. Kelley, T. Young, M. Vakil, R. horns, G. Upadhyaya, B. Ebrahimi, H. Yeon, F. Howard and A. Rios. Wilshire Oncology Group, La Verne, California. "Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in community based clinical practice." Proc Amer Soc Clin Oncol and Poster Presentation, 2006.
 
Cynthia L. Martel, MD, PhD, Cary A. Presant, MD, FACP, Ben Ebrahimi, MD, Gargi Upadhyaya, MD, Mayank Vakil, MD, Christina Yeon, MD, Linda D. Bosserman, MD, FACP, and Richard Horns, MD. "Bevacizumab-related toxicities: association of hypertension and proteinuria." Community Oncology 3(2):90-93, 2006.
 
Yeon CH and Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 12(5): 391-409, 2005.; Bosserman LD, Horns RC, Presant CA, Vakil MJ, Upadhyaya GH, Martel CL, Ebrahimi B, Yeon CH. Development and Implementation of Effective Quality Guidelines in Community Cancer Centers: The Cancer Quality Program (CQP) [abstract]. Proc Amer Soc Clin Oncol 24, 2005.
 
Horns RC, Bosserman LD, Presant CA, Vakil MJ, Upadhyaya GH, Martel CL, Ebrahimi B, Yeon CH. Increasing Accrual to Clinical Trials in Community Cancer Centers: A Successful Method Using Electronic Medical Records [abstract]. Proc Amer Soc Clin Oncol 24, 2005.
 
Ebrahimi B, Martel B, Horns RC, Upadhyaya GH, Vakil MJ, Yeon CH, Bosserman LD and Presant CA. Heterogeneous Monitoring for and Management of Bevacizumab (BE) Toxicity (T): Development of Standardized Guidelines for Monitoring (mon) and Treatment (tre) of Bevacizumab Toxicity Syndrome (BETS) [abstract]. Proc Amer Soc Clin Oncol 24, 2005.
 
  • American Society of Clinical Oncology (ASCO)
  • American Society of Hematology
Back To Top